The Evolution of Buprenorphine Virtual Training
Free Webinar: “The Evolution of Buprenorphine: OUD and Pain Treatment, Long-Acting Injectables, Novel Induction Strategies and More….”
Buprenorphine is a unique opioid with a markedly distinct pharmacokinetic and pharmacodynamic profile versus other opioids. It has been available as a pain analgesic since the 1970’s and approved for use in treatment of opioid use disorder for almost two decades in the United States. As a treatment for opioid use disorder, the increase in prescribing has been driven by the strong evidence demonstrating improved outcomes, increased retention in treatment, and decreased morbidity and mortality associated with its treatment. And now, with mounting evidence of its’ potent analgesia, superior safety profile and patient tolerability there has been a parallel increase in buprenorphine’s utilization across a broad array of pain conditions. Therefore, as medical providers more frequently encounter patients on buprenorphine therapy for either opioid use disorder or pain conditions, they must be prepared to discuss important considerations regarding the unique aspects of buprenorphine treatment including current indications and prescribing recommendations, available formulations. induction and bridging strategies, transitioning between full opioid agonists, and potential challenges in treatment. This training will review the unique aspects of buprenorphine pharmacology and how that translates into clinical practice. The training will also review the most recently published recommendations regarding novel induction strategies and address concerns regarding precipitated withdrawal in various clinical scenarios. Lastly, the training will review the upcoming new extended-release buprenorphine formulation currently scheduled to be available in mid-December 2021. _____________________________________________
TRAINER BIO Kerry Hettinger, PharmD, RPh Dr. Hettinger a registered pharmacist in Kentucky and Indiana and has served as a PharmD Trainer and Technical consultant for the Hazelden Betty Ford Foundation Professional Education Continuum Solutions Division since 2017. She currently serves on the Board of Directors for the Kentucky Harm Reduction Coalition and is an active member in several professional pharmacy organization promoting the role of the pharmacist in the multidisciplinary addiction care team. In her role as PharmD TTA Consultant, Dr. Hettinger has been passionately involved in providing pharmacotherapy education on addiction and addictive substances to healthcare professionals across the United the States. She has authored many presentations focused on the neurobiology and treatment of substance use disorders, psychopharmacology, medications for the treatment of opioid use disorder, and opioid stewardship initiatives. Dr. Hettinger has appeared as a featured speaker at several State Opioid Conferences and continues to provide direct training and clinical consultative services to healthcare professionals across healthcare settings. Prior to joining the Hazelden Betty Ford Foundation, Dr. Hettinger held positions in Kentucky independent and corporate retail pharmacies where she was involved in launching state’s first pharmacy-delivered addiction services.
At the end of this 2 Hr. training participants will be able to:
1. Review the pharmacokinetic and pharmacodynamic properties of buprenorphine and its’ safety and efficacy profiles in the treatment of opioid use disorder and pain.
2. Discuss current recommendations, approaches, and clinical considerations of acute pain management in the buprenorphine patient.
3. Identify the advantages, induction and maintenance strategies of the available extended-release buprenorphine injectable formulations Sublocade and Brixadi.
4. Describe alternative buprenorphine induction models for OUD and pain patients including, the Bernese Method (micro-dosing), “Rapid” micro-induction and transdermal patch bridging.